Cancer Radiation Therapy |
|
|
Clinical Trial: Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients with Locally Advanced Prostate Cancer
This study is currently recruiting patients.
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin or leuprolide may stop the adrenal glands from producing androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy, hormone therapy, and radiation therapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy, hormone therapy, and radiation therapy in treating patients who have locally advanced prostate cancer.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| adenocarcinoma of the prostate stage III prostate cancer | Drug: carboplatin Drug: estramustine Drug: goserelin Drug: leuprolide Drug: paclitaxel Procedure: chemotherapy Procedure: endocrine therapy Procedure: hormone therapy Procedure: neoadjuvant therapy Procedure: radiation therapy Procedure: releasing factor agonist therapy | Phase II |
MedlinePlus related topics: Prostate Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Neoadjuvant Paclitaxel, Estramustine, Carboplatin, and Androgen Ablation Followed By Radiotherapy in Patients With Poor-Prognosis Locally Advanced Prostate Cancer
OBJECTIVES:
- Determine the feasibility and safety of paclitaxel, estramustine, carboplatin, and androgen ablation followed by radiotherapy in patients with poor-prognosis locally advanced prostate cancer.
- Determine the progression-free survival and time to prostate specific antigen failure in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive paclitaxel IV over 1 hour once weekly; oral estramustine three times a day, five days a week; and carboplatin IV over 1 hour once monthly. Treatment repeats every 4 weeks for 4 courses.
Patients also receive gonadotropin-releasing hormonal therapy comprising either goserelin subcutaneously or leuprolide intramuscularly once monthly. Treatment repeats every 4 weeks for 6 courses.
After the completion of chemotherapy, patients undergo radiotherapy once daily on weeks 17-24.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 4 years.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study within 1.5 years.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the prostate with one of the following prognostic factors:
- Tx N0, baseline prostate specific antigen (PSA) greater than 20 ng/mL, and Gleason score at least 7
- T3b-4 N0, any baseline PSA, and any Gleason score
- No pelvic lymph node disease requiring pelvic radiotherapy
- No metastatic disease by bone scan, CT scan, or MRI
PATIENT CHARACTERISTICS: Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGOT no greater than 1.5 times ULN
Renal:
- Creatinine no greater than 1.5 times ULN
Cardiovascular:
- No significant cardiovascular disease
- No New York Heart Association class III or IV congestive heart failure
- No active angina pectoris
- No myocardial infarction within the past 6 months
- No history of hemorrhagic or thrombotic cerebral vascular accident
- No deep vein thrombosis within the past 6 months
Pulmonary:
Other:
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: Biologic therapy:
- No prior immunotherapy for prostate cancer
- No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF)
Chemotherapy:
- No prior chemotherapy for prostate cancer
- No other concurrent anticancer chemotherapy
Endocrine therapy:
- No more than 6 weeks of prior androgen deprivation therapy
- No other concurrent anticancer hormonal therapy except steroids for adrenal failure and/or hormones for nondisease-related conditions (e.g., insulin for diabetes)
Radiotherapy:
- See Disease Characteristics
- No prior radiotherapy for prostate cancer
- No other concurrent anticancer radiotherapy
Surgery:
- At least 4 weeks since prior major surgery
Other:
- No prior alternative therapy (e.g., PC-SPES) for prostate cancer
- No concurrent alternative medicine (e.g., PC-SPES or saw palmetto) or large quantities of vitamins
- No other concurrent anticancer therapy
Location and Contact Information
Alabama
Northeast Alabama Regional Medical Center, Anniston, Alabama, 36207, United States; Recruiting
California
Naval Medical Center - San Diego, San Diego, California, 92134-3202, United States; Recruiting
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States; Recruiting
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States; Recruiting
UCSF Comprehensive Cancer Center, San Francisco, California, 94115, United States; Recruiting
Veterans Affairs Medical Center - San Diego, San Diego, California, 92161, United States; Recruiting
Veterans Affairs Medical Center - San Francisco, San Francisco, California, 94121, United States; Recruiting
Delaware
CCOP - Christiana Care Health Services, Newark, Delaware, 19713, United States; Recruiting
District of Columbia
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, 20007, United States; Recruiting
Veterans Affairs Medical Center - Washington, DC, Washington, District of Columbia, 20422, United States; Recruiting
Walter Reed Army Medical Center, Washington, District of Columbia, 20307-5001, United States; Recruiting
Florida
Broward General Medical Center, Fort Lauderdale, Florida, 33316, United States; Recruiting
CCOP - Mount Sinai Medical Center, Miami Beach, Florida, 33140, United States; Recruiting
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, 33021, United States; Recruiting
Illinois
CCOP - Illinois Oncology Research Association, Peoria, Illinois, 61615-7828, United States; Recruiting
Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States; Recruiting
University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States; Recruiting
Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, 60612, United States; Recruiting
West Suburban Center for Cancer Care, River Forest, Illinois, 60305, United States; Recruiting
Indiana
CCOP - Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States; Recruiting
Fort Wayne Medical Oncology and Hematology, Incorporated, Fort Wayne, Indiana, 46885-5099, United States; Recruiting
Iowa
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, 52242-1009, United States; Recruiting
Kentucky
Baptist Hospital East - Louisville, Louisville, Kentucky, 40207, United States; Recruiting
Maryland
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201, United States; Recruiting
Massachusetts
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States; Recruiting
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, 01655, United States; Recruiting
Michigan
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph, Saint Joseph, Michigan, 49085, United States; Recruiting
Minnesota
University of Minnesota Cancer Center, Minneapolis, Minnesota, 55455, United States; Recruiting
Veterans Affairs Medical Center - Minneapolis, Minneapolis, Minnesota, 55417, United States; Recruiting
Missouri
CCOP - Kansas City, Kansas City, Missouri, 64131, United States; Recruiting
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, 65203, United States; Recruiting
Missouri Baptist Cancer Center, Saint Louis, Missouri, 63131, United States; Recruiting
Siteman Cancer Center at Barnes-Jewish Hospital, Saint Louis, Missouri, 63110, United States; Recruiting
Veterans Affairs Medical Center - Columbia (Truman Memorial), Columbia, Missouri, 65201, United States; Recruiting
Nebraska
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, 68198-7680, United States; Recruiting
Nevada
CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, 89106, United States; Recruiting
Veterans Affairs Medical Center - Las Vegas, Las Vegas, Nevada, 89106, United States; Recruiting
New Hampshire
New Hampshire Oncology-Hematology, PA - Hooksett, Hooksett, New Hampshire, 03106, United States; Recruiting
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756-0002, United States; Recruiting
New Jersey
Cancer Institute of New Jersey at the Cooper University Hospital, Camden, New Jersey, 08103, United States; Recruiting
New York
CCOP - North Shore University Hospital, Manhasset, New York, 11030, United States; Recruiting
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., East Syracuse, New York, 13057, United States; Recruiting
Elmhurst Hospital Center, Elmhurst, New York, 11373, United States; Recruiting
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States; Recruiting
Mount Sinai Medical Center, New York, New York, 10029, United States; Recruiting
New York Weill Cornell Cancer Center at Cornell University, New York, New York, 10021, United States; Recruiting
North Shore University Hospital, Manhasset, New York, 11030, United States; Recruiting
Queens Cancer Center of Queens Hospital, Jamaica, New York, 11432, United States; Recruiting
Roswell Park Cancer Institute, Buffalo, New York, 14263-0001, United States; Recruiting
SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States; Recruiting
Veterans Affairs Medical Center - Buffalo, Buffalo, New York, 14215, United States; Recruiting
Veterans Affairs Medical Center - Syracuse, Syracuse, New York, 13210, United States; Recruiting
North Carolina
Cape Fear Valley Medical Center, Fayetteville, North Carolina, 28302-2000, United States; Recruiting
CCOP - Southeast Cancer Control Consortium, Goldsboro, North Carolina, 27534-9479, United States; Recruiting
Comprehensive Cancer Center at Moore Regional Hospital, Pinehurst, North Carolina, 28374, United States; Recruiting
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1082, United States; Recruiting
Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States; Recruiting
Lenoir Memorial Cancer Center, Kinston, North Carolina, 28503-1678, United States; Recruiting
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, 27599-7295, United States; Recruiting
NorthEast Oncology Associates - Concord, Concord, North Carolina, 28025, United States; Recruiting
Veterans Affairs Medical Center - Asheville, Asheville, North Carolina, 28805-9913, United States; Recruiting
Veterans Affairs Medical Center - Durham, Durham, North Carolina, 27705, United States; Recruiting
Zimmer Cancer Center at New Hanover Regional Medical Center, Wilmington, North Carolina, 28402-9025, United States; Recruiting
Ohio
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio, 43210-1240, United States; Recruiting
Oklahoma
Oklahoma University Medical Center, Oklahoma City, Oklahoma, 73104, United States; Recruiting
Pennsylvania
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, 15224, United States; Recruiting
Rhode Island
Miriam Hospital at Lifespan, Providence, Rhode Island, 02906, United States; Recruiting
Texas
Veterans Affairs Medical Center - Dallas, Dallas, Texas, 75219, United States; Recruiting
Vermont
Vermont Cancer Center at University of Vermont, Burlington, Vermont, 05401-3498, United States; Recruiting
Virginia
Martha Jefferson Hospital, Charlottesville, Virginia, 22902, United States; Recruiting
MBCCOP - Massey Cancer Center, Richmond, Virginia, 23298-0037, United States; Recruiting
Oncology and Hematology Associates of Southwest Virginia, Incorporated - Roanoke, Roanoke, Virginia, 24014, United States; Recruiting
Virginia Oncology Associates - Norfolk, Norfolk, Virginia, 23502, United States; Recruiting
West Virginia
St. Mary's Medical Center, Huntington, West Virginia, 25701, United States; Recruiting
William K. Kelly, DO, Study Chair, Memorial Sloan-Kettering Cancer Center
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: October 2004
Last Updated: April 5, 2005
Record first received: June 6, 2001
ClinicalTrials.gov Identifier: NCT00016913
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 8, 2005

Not Signed In -


